← Back to all postsTreatment Info

ECM Booster vs Skin Booster: What's the Difference?

ECM boosters replace dermal structure directly; skin boosters stimulate your own collagen

📅 Last updated: November 2026

💡 At a glance · ECM boosters (Re2O, CellREDM, Juveàcell) inject the extracellular matrix of human acellular dermal matrix (hADM) — collagen, elastin and glycoproteins with the cells removed — to directly refill the dermis. · Conventional skin boosters (Rejuran, PDRN "salmon DNA", Juvelook, HA "glass skin" boosters, Profhilo) hydrate or signal your own fibroblasts to make collagen. · One-line answer: thinned dermis with pores, laxity and lost density → ECM booster; dehydration, fine lines and texture → PN; volume plus firmness → collagen stimulators. · In a 20-week split-face randomized trial published in 2026, the hADM booster improved density, volume, elasticity, pore area and hydration more than hyaluronic acid, with no serious adverse events (Lee et al., 2026).

Why the two names get confused

ECM boosters (ECM skin boosters, Re2O/Elravie Re2O, CellREDM, Juveàcell, hADM skin boosters) and skin boosters (スキンブースター, 水光针/水光針, สกินบูสเตอร์) look like the same procedure. Both are injected into the dermis, and both promise better texture, firmness and pores. So in consultation we often hear, "Isn't Re2O just another skin booster?"

Yes — by classification an ECM booster sits under the skin-booster umbrella. What differs is what it does inside the skin. Conventional skin boosters either add water or send cells a signal to get to work; an ECM booster brings in the scaffold (matrix) the cells work on. That one difference changes how fast results appear, which concerns they suit, and how pain and downtime feel. In Korea, searches for Re2O and CellREDM rose sharply through 2026, and "how is an ECM booster different from a skin booster?" became a search query in its own right.

What is a skin booster? — One umbrella, four families

A skin booster is any "bioactive material injected into the dermis to support skin function" (Rho et al., 2024, Archives of Plastic Surgery). By ingredient they fall into four families.

FamilyRepresentative productsWhat it does in the skin
Hydration (HA)HA glass-skin boosters, Profhilo, SkinviveHyaluronic acid binds water → immediate hydration and glow
Regenerative signalling (PN/PDRN)Rejuran, Rejuran HB+, PDRN salmon injectionsSalmon DNA fragments signal fibroblasts → texture, deep dryness, fine lines
Collagen stimulators (PDLLA/PLLA/CaHA)Juvelook, Juvelook Volume, Sculptra, RadiesseBiodegradable particles trigger collagen via a controlled foreign-body response → firmness, volume
Cell signalling (exosomes)Exosome boosters (ASCE+ etc.)Secreted vesicles deliver anti-inflammatory and repair signals, usually paired with laser or microneedling

What they share: your body does the building. HA adds water but not collagen; PN and PDLLA need roughly 4–12 weeks before new collagen forms. In a 15-patient case series combining microneedling with PDLLA (Juvelook), three sessions three weeks apart produced visible pore and texture improvement at 12 and 22 weeks (Wan et al., 2025, Plastic and Reconstructive Surgery – Global Open). PN products likewise show hydration, texture and fine-line gains across many clinical reports, though reviews consistently note that large randomized trials are still limited (Rho et al., 2024).

What is an ECM booster? — Bringing collagen in, not asking the skin to make it

An ECM booster takes donated human dermis, removes cells and DNA (decellularization), and processes the remaining extracellular matrix — the mesh that holds skin cells in place — into fine particles (powder) or a liquid for injection into the dermis. The products used in Korea are Re2O (L&C Bio), CellREDM (Hans Biomed) and Juveàcell (VAIM). All are regulated as human-tissue products by Korea's Ministry of Food and Drug Safety (MFDS); Re2O and CellREDM additionally state compliance with American Association of Tissue Banks (AATB) standards.

The key point is that the material injected is already a finished dermal structure. Re2O is roughly 80% collagen, 3% elastin and 0.4% sulfated glycosaminoglycans, with residual DNA kept below 50 ng/mg (Lee et al., 2026). Sheet-form acellular dermal matrix has been used in reconstructive surgery for decades and is known to vascularize and integrate with surrounding tissue over 3–6 months (Lee et al., 2015, Biomaterials); the injectable particulate version is what we call an ECM booster (Park et al., 2017, Tissue Engineering and Regenerative Medicine).

Clinical evidence: a 20-week split-face, randomized, double-blinded trial

Researchers from Yonsei University College of Medicine published a study in International Journal of Molecular Sciences in February 2026 (Lee YI et al., 2026). Twenty adults aged 30–65 (mean 54.7) received a single injection of Re2O plus HA on one side of the face and HA skin booster alone on the other, with 20 weeks of follow-up. Findings:

  • Skin density and volume: significantly greater on the hADM side at every time point (ultrasound density, 3D volume)
  • Pore area: decreased on both sides, with a larger reduction on the hADM side from week 12 onward
  • Elasticity (Cutometer): hADM side superior at weeks 4 and 20
  • Hydration and TEWL: hADM side more hydrated from week 8; barrier indices better at weeks 8 and 20
  • Nasolabial fold depth, under-eye wrinkles, pigmentation area: greater reduction on the hADM side, with measurable lifting of the periorbital and cheek contours at week 20
  • Satisfaction (GAIS): physician and patient scores higher on the hADM side from week 8 through 20
  • Safety: no serious adverse events; transient redness and swelling resolved without treatment

In animal and tissue models, fibroblasts migrated into the particles within one week and new collagen formed at the particle–skin interface. The authors stressed that the ECM booster integrates while lowering inflammatory signals (IL-6, TNF-α) rather than forcing collagen through inflammation. They also stated the limits: 20 participants, 20 weeks, and a test product that contained HA, so the standalone effect cannot be fully separated.

Not all ECM boosters are the same: powder-type Re2O and CellREDM vs liquid-type Juveàcell

Korea's ECM booster market started with Re2O (L&C Bio) and CellREDM (Hans Biomed) in 2025, and Juveàcell (VAIM) joined in 2026. All three share the hADM root but diverge in formulation and particle design.

ItemRe2OCellREDMJuveàcell
MakerL&C BioHans Biomed (distributed by Hugel)VAIM (maker of Juvelook)
FormPowder, mixed with HA/saline right before injectionPowder, mixed before injectionLiquid prefilled syringe (3% / 8%); powder versions (V, G) also available
Particle designStandard about 75 µm (refined from the original 100 µm); Fine about 50 µm; V more than twice the standard size (unveiled October 2026)Single grade, about 75 µmLiquid form said to reduce clumping; concentration sets the use (3% texture, 8% volume)
DecellularizationAlloClean process (manufacturer term)Micronized hADM processSupercritical CO₂ (ECell), no surfactants
Published clinical data2026 split-face randomized double-blinded trial (Lee et al.)Manufacturer and clinic dataManufacturer and clinic data (no peer-reviewed trial identified as of November 2026)
Stated strengthsDensity restoration, particle line-up by indicationShallow, wide placement for thin or sensitive skinUniform injection without dilution, lower nodule concern, single-session results

Powder types let the physician tune concentration and volume by mixing with HA or saline just before injection; the trade-off is that particle size and mixing can leave a temporary gritty feel. Liquid types skip dilution for more uniform placement and are promoted as lower-risk for nodules, but no peer-reviewed trial has been published yet, so durability and safety data are less mature than for the powder products. To date the only product with a published randomized human trial is Re2O, and those results should not be transferred wholesale to Juveàcell.

Head-to-head comparison

ItemECM booster (Re2O, CellREDM, Juveàcell)Conventional skin boosters (Rejuran, Juvelook, HA etc.)
Main ingredientHuman-derived acellular dermal matrix (hADM) ECM, as powder or liquidHA / salmon PN-PDRN / PDLLA-PLLA-CaHA / exosomes
MechanismDirectly replaces finished dermal structure; cells migrate in and integrateHydrates, or stimulates fibroblasts to produce collagen
Main indicationsThinned dermis, low density, enlarged pores, fine lines, laxityDryness and texture (HA, PN); firmness and volume (PDLLA, PLLA); inflamed skin (exosomes)
OnsetRelatively fast (density and volume from the first measurement; pore gap widens after week 12)HA immediate; PN and PDLLA gradual over 4–12 weeks
SessionsAssessable after one session; add if neededTypically about 3 sessions, 3–4 weeks apart
PainReported as comparatively mild thanks to fine particlesRejuran is viscous and notably painful; HA and exosomes mild
DowntimeNeedle marks and mild swelling 1–3 days; some feel fine particles for a few weeksPapules and swelling 1–3 days (varies by product)
SourceDonor human tissue (MFDS human-tissue regulation)Synthetic HA, salmon DNA, synthetic polymers, cell-culture media
PriceConsultation requiredConsultation required

Which one is right for you?

  • "I've had several skin boosters and my pores and firmness haven't changed" → Often the dermis is too thin to respond to stimulation. An ECM booster (Re2O) that adds structure is the first option to consider.
  • "Tightness, dullness and makeup not sitting well are my main concerns" → If hydration and texture are the goal, PN products like Rejuran or HA boosters such as Profhilo make sense.
  • "My cheeks have hollowed and lost firmness" → For volume plus collagen, collagen stimulators such as Juvelook Volume or Sculptra come first.
  • "I'm sensitive to pain" → Undiluted Rejuran is painful; an ECM booster or a lidocaine-containing formula (Rejuran HB+) is an alternative.
  • "I'm worried about lumps or nodules" → Liquid Juveàcell or the finer-particle lines (Re2O Fine, CellREDM) are worth considering, bearing in mind that liquid types have less published data.
  • "Human-derived material makes me uncomfortable" → ECM boosters are decellularized donor tissue and some people prefer to avoid them. Synthetic polymers (PDLLA) or PN products are the alternative. Always ask about sourcing and quality standards.

Treatments that pair well

An ECM booster adds material; lifting devices contract and reorganize tissue with heat, so they act on different layers. Heating with Ultherapy (SMAS), Thermage (deep dermis) or Potenza (microneedle RF) and then filling the dermis with ECM lets the two work at different depths. PN and exosomes, by contrast, are usually used right after laser or microneedling to calm and repair the skin.

How we approach it at DIORE Clinic

At DIORE Clinic we frequently combine Re2O with lifting devices on the same day. Because each acts at a different depth there is little added strain on the skin, and we order the steps from least to most invasive: Ultherapy or Thermage first, Potenza next, and the Re2O injection last. Because Re2O allows density and firmness to be assessed after a single session, for international patients with a short stay in Korea we design a "one visit, see the result" plan. Series-based treatments such as Rejuran or Juvelook, which assume about three sessions, are recommended only after checking the length of stay.

Frequently asked questions

Q1. I can feel small granules under my skin after Re2O — is that normal?

Until the ECM particles integrate, some people feel fine granules or a slight temporary raise under the skin. This is reported to fade naturally over a few weeks to 2–3 months, and in the 20-week trial only mild redness and swelling were seen, with no serious adverse events. If pain, heat or redness accompanies it, or it grows, contact the treating clinic right away.

Q2. Can I have an ECM booster together with Rejuran?

Because their mechanisms differ, combination is possible in principle, but rather than placing both in the same layer on the same day, it is more common to stagger them or assign roles by area — for example ECM for density and pores, PN for under-eye fine lines and deep dryness.

Q3. How long does Re2O last? Is one session enough?

Sheet-form acellular dermis is known to integrate over 3–6 months, and in the 20-week trial of the injectable form, density, volume and elasticity held or improved through week 20 after one session. Longer-term data are still accumulating. Clinically it is reasonable to assess after one session and decide on additional treatment by skin condition.

Q4. Re2O, CellREDM or Juveàcell — which is better?

All three are hADM-derived ECM boosters with a similar direction of effect; the differences are formulation and particle design. Re2O offers three particle grades — standard (about 75 µm), Fine (about 50 µm) and V (more than twice the standard) — for different areas; CellREDM is a single powder at about 75 µm aimed at shallow, wide placement in thin or sensitive skin; Juveàcell is a ready-to-use liquid prefilled syringe (3%/8%) promoted for uniform injection and lower nodule concern. The only one with a published split-face randomized human trial is Re2O; the other two rest on manufacturer and clinical-practice data. The right choice depends on skin thickness, target area and how much evidence you want behind the product.

Q5. When can I wash my face, wear makeup and exercise?

Wash gently on the day until needle marks close; makeup is usually fine from the next day. Avoid strenuous exercise, saunas and alcohol for about 48 hours, and keep up sun protection throughout the integration period. Guidance varies by product and skin, so follow your treating clinician's instructions.

Takeaway

The difference between ECM boosters and skin boosters is not better or worse but refill versus stimulate. If your skin still has material to respond with, a stimulating skin booster is enough; if the dermis has thinned and there is little left to stimulate, an ECM booster lays that foundation first. The 2026 randomized trial showed this approach can outperform hyaluronic acid on density, firmness and pores — within the limits of 20 participants and 20 weeks.

ℹ️ This content is for general medical information and does not replace individual consultation. Results vary by individual skin condition; for accurate diagnosis and advice, please consult a qualified aesthetic medicine professional.

References

  • Lee YI, Chau NH, Nguyen NH, Ham S, Baek Y, Kim J, Lee JH. Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration: An Integrated Randomized, Split-Face, Double-Blinded Clinical Trial and Preclinical Study. Int J Mol Sci. 2026;27(5):2193. doi:10.3390/ijms27052193
  • Rho NK, Kim HS, Kim SY, Lee W. Injectable "Skin Boosters" in Aging Skin Rejuvenation: A Current Overview. Arch Plast Surg. 2024;51(5):528-541. doi:10.1055/a-2366-3436
  • Lee JH, Kim HG, Lee WJ. Characterization and tissue incorporation of cross-linked human acellular dermal matrix. Biomaterials. 2015;44:195-205.
  • Park TH, Choi WY, Lee JH, Lee WJ. Micronized Cross-Linked Human Acellular Dermal Matrices: An Effective Scaffold for Collagen Synthesis and Promising Material for Tissue Augmentation. Tissue Eng Regen Med. 2017;14:517-523.
  • Wan J, Seo SB, Yoon SE, Yi KH. The Efficacy of Combined Microneedling and Topical Poly-d,l-lactic Acid (Juvelook) Application for Facial Pore Reduction and Skin Texture Improvement. Plast Reconstr Surg Glob Open. 2025;13(6):e6838.
  • ClinicalTrials.gov NCT07155278. Efficacy & Safety of hADM Skin Booster (Yonsei University, Severance Hospital). 2024-2025.
Dr. Kwang Yeol Lee
Chief Director, DIORE Clinic · Aesthetic Medicine
About Dr. Lee →